HCID 10861009, compound → 4-Cyclohexyl-4-[(1H-1,2,4-triazol-1-yl)methyl]piperidine

HRID 1795176Notes

Reaction equation

HRID 1795176 reaction equation
C(OC([N:8]1[CH2:13][CH2:12][C:11]([CH:20]2[CH2:25][CH2:24][CH2:23][CH2:22][CH2:21]2)([CH2:14][N:15]2[CH:19]=[N:18][CH:17]=[N:16]2)[CH2:10][CH2:9]1)=O)(C)(C)C>FC(F)(F)C(O)=O.ClCCl.O>[CH:20]1([C:11]2([CH2:14][N:15]3[CH:19]=[N:18][CH:17]=[N:16]3)[CH2:12][CH2:13][NH:8][CH2:9][CH2:10]2)[CH2:21][CH2:22][CH2:23][CH2:24][CH2:25]1

Participants

3

Reactant 1

HCID 10861009HCID 10861009, compound

Product 1

HCID 129914504-Cyclohexyl-4-[(1H-1,2,4-triazol-1-yl)methyl]piperidine

Reagents, catalysts & solvents 1

HCID 18672661TFA dichloromethane waterSolvent

Procedure

To a solution of trifluoroacetic acid/dichloromethane/water (1:1:0.1, 10 mL) is added 4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester, 3, (3.5 g, 10 mmol) which was obtained in the procedure herein above and the reaction mixture is allowed to stir for 30 to 60 minutes. The reaction solution is then concentrated in vacuo and partitioned between aqueous NaHCO3 and EtOAc. The organic phase is concentrated in vacuo and the crude product purified by HPLC over silica gel to afford the desired product.

Workup

  1. custom(3.5 g, 10 mmol) which was obtained in the procedure herein above and the reaction mixture
  2. concentrationThe reaction solution is then concentrated in vacuo
  3. custompartitioned between aqueous NaHCO3 and EtOAc
  4. concentrationThe organic phase is concentrated in vacuo
  5. customthe crude product purified by HPLC over silica gel

Sources & evidence

ORD record
ord-489934a29b7f46258165e4134c0f57d2
Source dataset
uspto-grants-2006_04
Patent number
US07026335B2

Reaction notes

Loading…